Abeona Therapeutics Inc
NASDAQ:ABEO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abeona Therapeutics Inc
Interest Expense
Abeona Therapeutics Inc
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abeona Therapeutics Inc
NASDAQ:ABEO
|
Interest Expense
$3.7m
|
CAGR 3-Years
72%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
90%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Expense
$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Expense
$1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Expense
$2.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Expense
$13.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Expense
$43.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
12%
|
|
Abeona Therapeutics Inc
Glance View
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in New York City, New York and currently employs 90 full-time employees. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.
See Also
What is Abeona Therapeutics Inc's Interest Expense?
Interest Expense
3.7m
USD
Based on the financial report for Dec 31, 2025, Abeona Therapeutics Inc's Interest Expense amounts to 3.7m USD.
What is Abeona Therapeutics Inc's Interest Expense growth rate?
Interest Expense CAGR 10Y
90%
Over the last year, the Interest Expense growth was -11%. The average annual Interest Expense growth rates for Abeona Therapeutics Inc have been 72% over the past three years , -2% over the past five years , and 90% over the past ten years .
